BioCentury | Apr 11, 2017
Distillery Therapeutics

Hepatic

...O304 in Phase II testing for Type II diabetes and Phase I testing for obesity. Kareus Therapeutics S.A....
BioCentury | Jan 7, 2013
Clinical News

KU-046: Phase I started

...Quintiles agreed to make an equity investment in Kareus and provide clinical support to develop Kareus'...
...Quintiles agreed to conduct a Phase I trial of KU-046 (see BioCentury, June 20, 2011). Kareus Therapeutics S.A....
...a generally recognized as safe (GRAS) molecule combined with a marketed non-Alzheimer's disease product using Kareus'...
BioCentury | Nov 21, 2011
Emerging Company Profile

Kareus: Linking up in AD

...new chemical entities by covalently linking two compounds for simultaneous dosing in a target tissue. Kareus...
...K. Anji Reddy believed the technologies were still worth pursuing, so he founded and financed Kareus...
...India Kareus Therapeutics S.A. , La Chaux-de-Fonds, Switzerland Quintiles Transnational Corp. , Research Triangle Park, N.C. Sidebars Kareus Therapeutics S.A....
BioCentury | Jun 20, 2011
Company News

Kareus, Quintiles deal

...CRO Quintiles will make an equity investment in Kareus and provide clinical support to develop Kareus'...
...two preclinical programs for Alzheimer's disease and diabetes. Quintiles will make a seven-figure investment in Kareus...
...CRO Quintiles will make an equity investment in Kareus and provide clinical support to develop Kareus'...
BioCentury | Jun 13, 2011
Company News

Quintiles invests in Kareus

...make an equity investment in Kareus Therapeutics S.A. (La Chaux-de-Fonds, Switzerland) and provide clinical support to develop Kareus'...
...two preclinical programs for Alzheimer's disease and diabetes. Quintiles will make a seven-figure investment in Kareus...
...to Quintiles' clinical services on a shared-risk basis. Quintiles will conduct Phase I trials for Kareus'...
Items per page:
1 - 5 of 5
BioCentury | Apr 11, 2017
Distillery Therapeutics

Hepatic

...O304 in Phase II testing for Type II diabetes and Phase I testing for obesity. Kareus Therapeutics S.A....
BioCentury | Jan 7, 2013
Clinical News

KU-046: Phase I started

...Quintiles agreed to make an equity investment in Kareus and provide clinical support to develop Kareus'...
...Quintiles agreed to conduct a Phase I trial of KU-046 (see BioCentury, June 20, 2011). Kareus Therapeutics S.A....
...a generally recognized as safe (GRAS) molecule combined with a marketed non-Alzheimer's disease product using Kareus'...
BioCentury | Nov 21, 2011
Emerging Company Profile

Kareus: Linking up in AD

...new chemical entities by covalently linking two compounds for simultaneous dosing in a target tissue. Kareus...
...K. Anji Reddy believed the technologies were still worth pursuing, so he founded and financed Kareus...
...India Kareus Therapeutics S.A. , La Chaux-de-Fonds, Switzerland Quintiles Transnational Corp. , Research Triangle Park, N.C. Sidebars Kareus Therapeutics S.A....
BioCentury | Jun 20, 2011
Company News

Kareus, Quintiles deal

...CRO Quintiles will make an equity investment in Kareus and provide clinical support to develop Kareus'...
...two preclinical programs for Alzheimer's disease and diabetes. Quintiles will make a seven-figure investment in Kareus...
...CRO Quintiles will make an equity investment in Kareus and provide clinical support to develop Kareus'...
BioCentury | Jun 13, 2011
Company News

Quintiles invests in Kareus

...make an equity investment in Kareus Therapeutics S.A. (La Chaux-de-Fonds, Switzerland) and provide clinical support to develop Kareus'...
...two preclinical programs for Alzheimer's disease and diabetes. Quintiles will make a seven-figure investment in Kareus...
...to Quintiles' clinical services on a shared-risk basis. Quintiles will conduct Phase I trials for Kareus'...
Items per page:
1 - 5 of 5